Final Program [International Conference on AIDS (14th: 2002: Barcelona, Spain)]

Poster Exhibitions Tuesday July 9..

TuPeB4554 Relative bioavailability of stavudine (d4T)
extended-release (XR*) formulation after
coadministration with a light or high-fat meal in
healthy subjects
S Kaul, S Agarwala, H Hess, D Behr, P Nichola,
J D Xie, I Gale (United States)
TuPeB4555 Stavudine extended release (XR*): single-dose,
dose-proportionality study following oral
administration in healthy subjects
S Kaul, S Agarwala, H Hess, P Nichola, I Gale,
E O'Mara (United States)
TuPeB4556 Effective plasma levels of amprenavir in highly
challenging, naive HIV patients following a once
daily HAART regimen
V Garg, M Brill, L Beeler, I Pottage, A Rodriquiz,
R Campo, T Tanner, D Jayaweera (United States)
TuPeB4557 Nelfinavir (NFV) pharmacokinetics (PK) in HIV
infected children: who are at risk for
subtherapeutic plasma levels?
AS Bergshoeff P L A Fraaij, T F W Wolfs,
S PM Geelen, R de Groot, D M Burger
(The Netherlands)
TuPeB4558 Clinical efficacy of salvage regimens containing
both amprenavir and lopinavir/ritonavir as
compared to salvage regimens containing only
lopinavir/ritonavir stratified by NNRTI-experience
M Loutfy, C Thompson, M Trpeski, C Kovacs,
A Rachlis, J Goodhew, G Rubin, K Gough,
S Walmsley (Canada)
TuPeB4559 Concomitant use of non-nucleoside reverse
transcriptase inhibitors (NNRTI) decreases
exposure to saquinavir when used with a once
daily saquinavir (SQV) and low dose ritonavir
(RTV) dosing regimen
JG Baril R Leblanc, C Olivier (Canada)
TuPeB456o The pharmacokinetic interaction of
lopinavir/ritonavir and amprenavir in clinical
practice
H E Reynolds, S E Gibbons, J F Tjia, S H Khoo,
D J Back (United Kingdom)
TuPeB4561 Lopinavir/Ritonavir versus Rinonavir boosted
Saquinavir plasma levels
CJStephan, T Lutz, M Kurowski, P Gute,
S Staszewski (Germany)
TuPeB4562 Effectiveness of antiretrovirals in patients who
attend HIV clinics in Rio de Janeiro, Brazil
C B Hofer, M Schechter2, L H Harrison'
('United States; 2Brazil)
TuPeB4563 Impact of low dose ritonavir (rtv) on
pharmacokinetics (PK) of nelfinavir (NFV) and its
active metabolite M8 in HIV infected patients
F Rafi', L Nieto2, M Hernandez-Jacome2,
R J Pedro3, P Gargalianos4, G Felice5, A Lazzarin5,
R Tansley6, M Popescu7 (France; 2 Mexico; 3Brazil;
"Greece; s/taly; "United Kingdom; 7Switzerland)
TuPeB4564 Trans-f3-carotene and retinoids can effect human
cytochrome P450 3A4-mediated metabolism
B C Foster (Canada)
TuPeB4565 Assessment of the effect of nevirapine on the
pharmacokinetics of lopinavir/ritonavir (Kaletra~)
after multiple dosing in HIV-infected adults
R Bertz, C Foit, D Burt, K Grebner, T Marsh,
B Bernstein, S Brun, Y L Chiu, M King, A Hsu,
G R Granneman, E Sun (United States)
TuPeB4566 Correlation of nelfinavir efficacy,
pharmacokinetics (PK) and use of antacids in
treatment-naive HIV positive patients receiving

nelfinavir and 2 nucleosides
P H Hsyu A Chu (United States)

TuPeB4567 Population pharmacokinetics (PK) of nevirapine
(NVP) in an unselected cohort of HIV-1-infected
individuals
M M R de Maat, A D R Huitema, I W Mulder,
P L Meenhorst, E CM van Gorp, I H Beijnen
(The Netherlands)
TuPeB4568 Relationship between trough plasma
concentrations of HIV antiretroviral drugs and
virological response and mutations reversion in
gighaart trial (anrs 097)
G Peytavin M Legrand, C Duvivier, C Lamotte,
S Dominguez, C Delaugerre, D Costagliola,
V Calvez, C Katlama (France)
TuPeB4569 Effect of efavirenz and nevirapine on P-gp
expression: the impact on protease inhibitor
fluxing
L M Almond, B Chandler, P G Hoggard, A Owen,
S H Khoo, DI Back (United Kingdom)
TuPeB457o Indinavir/ritonavir 8oo00/oomg twice daily (BID)
should be taken with food to prevent toxic
indinavir peak plasma levels
R Aarnoutse', I Wasmuth2, G Fdtkenheuer2,
K Schneider2, P Reiss', D Burger, J Rockstroh2
('The Netherlands; 2Germany)
TuPeB4571 Predictivity of amprenavir plasma concentrations
on virological response in HIV-infected patients
treated with amprenavir/ritonavir containing
regimen: a Genophar substudy
G Peytavin C Lamotte, A G Marcelin,
C Delaugerre, H Aft-Mohand, M Bonmarchand,
P Bossi, N Ktorza, F Bricaire, D Costagliola,
C Katlama, V Calvez (France)
TuPeB4572 The pharmacokinetics of saquinavir/ritonavir
4oo00/400oo mg bid before, and after short- and longterm co-administration of efavirenz 6oo mg qd
R P G van Heeswik, C Cooper, K D Gallicano,
G Carignan, Y Khaliq, I Seguin, N Hawley, J Angel,
A D Badley, G Garber, D W Cameron (Canada)
TuPeB4573 Steady state pharmacokinetic (PK) of Lopinavir
(LPV) in combination with Nevirapine (NVP) or
Efavirenz (EFV)
O Degen, M Kurowski, J van Lunzen, T Buhk,
H jStellbrink (Germany)
TuPeB4574 Effects of human serum (HS) on protease
inhibitor (PI) and non-nucleoside reverse
transcriptase inhibitor (NNRTI) activity in a
phenotypic drug susceptibility assay
(PhenoSenseTM HIV).
K L Limoli, L H Trinh, GM Heilek-Snyder,
N S Hellmann, CJ Petropoulos (United States)
TuPeB4575 Use of therapeutic drug monitoring in clinical
practice
Dj Ward, M Zetoony (United States)
TuPeB4576 Nelfinavir (NFV), but not its major M8 metabolite,
inhibits systemic P-glycoprotein (P-gp) activity
during HIV therapy
I P Donahue, D Dowdy, K K Ratnam, I Price,
I McKinsey, D Unutmaz, I Nicotera, S Raffanti,
M Becker, D W Haas (United States)
TuPeB4577 Efficacy and safety of indinavir/ritonavir
combination in the era of pharmacological
monitoring
I B guiard-schmid, A H gbadoe, I M poirier,
C amiel, V schneider, G peytavin, G pialoux,
W Rozenbaum (France)
TuPeB4578 Safety and efficacy of nevirapine in patients who
do not tolerate efavirenz

A Woehrmann, N Schmeisser, I Rockstroh,
A Rubbert, C Wyen, K Schmitz, G Faetkenheuer
(Germany)
XIV International AIDS Conference BARCELONA - JULY 7-12

Tuesday

99